INTRODUCTION
In Egypt, breast cancer (BC) is the most common cancer among women, representing 18.9% of total cancer cases and 35.1% of cancer in women. Breast cancer patients receiving therapy require supportive care for the prevention and management of physical and psychosocial adverse effects of cancer and its treatments [1]. Patients undergoing cytotoxic chemotherapy require careful assessment of liver function both prior to and during therapy. Potential interactions between the liver and chemotherapy fall into two categories: Direct chemotherapy-induced hepatotoxicity and potentiation of preexisting liver disease, especially viral hepatitis [2] . Druginduced liver injury (DILI) has an estimated annual incidence between 10 and 15 per 10,000 to 100,000 persons exposed to prescription medications. DILI accounts for approximately 10% of all cases of acute hepatitis, and it is the most common cause of acute liver failure in the United States [3] . Viral hepatitis reactivation is one of the major challenges encountered during a variety of chemotherapy treatments. In the literature, there is a well-established association between hepatitis B virus (HBV) reactivation and some anti-cancer drugs, especially monoclonal antibodies. On the other hand, there is limited data concerning the reactivation of hepatitis Sheded 
Aim of the work:
To assess liver morbidity in breast cancer patients before and 3 months after chemotherapy to assess reactivation of viral hepatitis.
PATIENTS AND METHODS

Patients:
After approval of our ethics committee, this prospective study was performed in Oncology & nuclear medicine department at Suez Canal University hospital, Ismailia from June 2011 to December 2012. It included 88 breast cancer patients who consecutively attended the Oncology & Nuclear Medicine Department to receive chemotherapy during the study period.
Methods:
The chemotherapeutic regimens of each patient were given according to the standard protocol for the specific tumor type.
Liver profile (ALT, AST, Bilirubin, Albumin, PT & INR, and ultrasonography were done for all patients before starting chemotherapy, Tri-phasic CT abdomen were done if there were focal hepatic lesions & then 3 months after completing chemotherapy.
Viral markers (HBsAg, HBsAb, & Anti-HBcIgG, HCV Ab) were done for all consecutive breast cancer patients who received cytotoxic chemotherapy.
Patients who were positive for HCV Ab were subjected to HCV DNA by PCR to detect active viral replication & viremia.
Patients who were positive for HBsAg or HBcIgG were subjected to HBV DNA by PCR to detect active viral replication & viremia.
All patients included in the study were subjected for: A-History taking : Including personal, socio-demographic data, and present illness (age, sex, blood transfusion, past surgical procedure, intravenous drug abuse, jaundice, past or family history of viral hepatitis, and family history of viral hepatitis or breast cancer). 
B-
RESULTS
This study revealed a significant liver morbidity in breast cancer patients who were treated with chemotherapy.
Regarding socio-demographic characteristics: Mean age of patients was 50±11.1 years. Most of the patients (74 patients (84%)) are married. 66 patients (75%) came from urban areas, and 72 patients (82%) were un-employed. Regarding to their special habits, only one patient was smoker and no one was alcoholic (Table 1) .
Regarding HBV & HCV :
11 (12.5%) patients were HBV positive, while 9 (10.2%) patients were HCV positive. Before chemotherapy 9 patients (10.2%) & 11 patients (12.5%) had elevated ALT & AST respectively which increased after chemotherapy to 32 patients (36.4%) & 29 patients (33%) respectively with significant P-value. Two patients (2.3%) had low serum albumin which increased after chemotherapy to 18 patients (20.5%) with significant P-value. None of the patients had elevated S. bilirubin; while after chemotherapy 10 (11.4%) had elevated S. bilirubin with significant P-value. Also none of the patients had ascites or jaundice before chemotherapy, while after chemotherapy 5 patients (5.6%) & 6 patients (6.8%) developed ascites and jaundice respectively.
Regarding Metastatic HFLs, 5 patients (5.7%) had MHFLs before chemotherapy; while after chemotherapy 9 patients (10.2%) had MHFLs. 7 patients (8%) had splenomegaly before treatment which became 8 patients (9%) after chemotherapy.
Regarding Child score:
None of the patients had child B/C score before treatment, while after chemotherapy 6 patients (6.8%) developed child B/C score ( Table 2 ).
Regarding symptoms :
We found that 23 patients (26.4%) had loss of weight & appetite before chemotherapy which increased to 66 patients (76%) after chemotherapy with significant P-Value (<0.01), 15 patients (17%) had easy fatigability which increased to 73 patients (83%) after chemotherapy with significant P-Value (<0.01), and 20 patients (22.7%) had dyspepsia which increased to 62 patients (70.5%) after chemotherapy with significant P-Value (<0.01).
Regarding breast cancer symptoms (Pain, Skin changes, Nipple discharge), none of them showed significant change after chemotherapy (Table 3 , Figure 1 ).
Regarding HBV patients:
Before treatment, one patient had Positive HbsAg with positive HBV DNA by PCR & was treated by Tenofovir 300 mg once daily and after treatment her HBV DNR by PCR showed negative result. Ten people had positive HbcIgG & negative HBsAg before treatment, nine of them had negative HBV DNA by PCR and only one patient had positive HBV DNA by PCR & was treated by tenofovir 300 mg once daily and recheck of HBV DNA by PCR after finishing chemotherapy showed negative result.
However, 2 new cases (HbcIgG positive, HBsAg negative & HBV DNA PCR negative before Treatment) showed a positive PCR levels after chemotherapy for their breast cancer with mean of 48254 IU/ ml, and one of them had positive HBsAg, for them treatment with tenofovir 300 mg once daily was started (Table 4) .
Regarding Liver morbidity in HBV patients:
Before chemotherapy 2 patients (10.2%) had elevated ALT & AST respectively which increased after chemotherapy to 7 patients (63.6%) & 5 patients (45.5%) respectively. None of the patients had low serum albumin or elevated S. bilirubin before chemotherapy, while after treatment 5 patients (45.5%) had low level of serum albumin & 3 patients (27.3%) had elevated serum bilirubin. Also none of the patients had ascites or jaundice before chemotherapy, while after chemotherapy 1 patient (9.1%) & 2 patients (18.2%) developed ascites and jaundice respectively.
Regarding Child score: None of the patients had Child B/C score before treatment, while after chemotherapy 2 patients (18.2%) developed child B/C score (Table 5) .
Regarding HCV patients:
Before chemotherapy treatment, 9 patients had positive result for HCV Ab, from whom 1 patient completed antiviral therapy with DAAS since 3 years and achieved SVR, 2 patients had negative HCV RNA by PCR, while the other 6 patients had positive HCV RNA by PCR with mean of 698352 IU/ ml which increased to 2609409 IU/ ml after chemotherapy (Table 4) .
Regarding Liver morbidity in HCV patients:
Before chemotherapy 3 patients (33.3%) had elevated ALT & 4 patients (44.4%) had elevated AST respectively which increased after chemotherapy to 7 patients (77.8%) with significant Pvalue. None of the patients had low serum albumin or elevated S. bilirubin before chemotherapy, while after treatment 5 patients (55.6%) had low level of serum albumin & 5 patients (55.6%) had elevated serum bilirubin. Also none of the patients had ascites or jaundice before chemotherapy, while after chemotherapy 4 patient (44.4%) & 4 patients (44.4%) developed ascites and jaundice respectively with significant P-value.
Regarding Child score: None of the patients had Child B/C score before treatment, while after chemotherapy 4 patients (44.4%) developed Child B/C score ( Also most of the patients were not working (81.8%) and married (84%), this explained by the socio-demographic characterestics of Ismailia city
In agreement with other studies that reported hepatotoxicity of chemotherapy for breast cancer patients, Potential interactions between the liver and chemotherapy fall into two categories: Direct chemotherapy-induced hepatotoxicity and potentiation of preexisting liver disease, especially viral hepatitis or Drug-induced liver injury (DILI).
Before starting chemotherapy 10.2% & 12.5% of patients reported elevated ALT & AST respectively which increased after chemotherapy to 36.4% & 33% respectively with the mean of ALT & AST increased from 31.74 & 32.53 IU/ml before chemotherapy to 46.6 & 47.94 IU/ml respectively after chemotherapy, which agree with Ahn .,et. al. who reported that 12.3% of breast cancer patients had abnormalities in LFT before chemotherapy which increased to 34.8% after chemotherapy
[3,4&5].
Also total S. bilirubin elevated in 11.4% of patients, the mean value of total S. bilirubin increased from 0.61 mg/dl before starting chemotherapy to 1.07 mg/dl after chemotherapy, in agree with Chauhan et. al. who reported the mean value of total bilirubin was 0.30±1.3mg/dl before the starting of the treatment which increased after chemotherapy to 1.12 mg/dl [5].
While percentage of patients who had low level of s. albumin markedly increased from 2.3% to 20.5% after chemotherapy and the mean value of S. albumin decreased from 4.07 gm/dl before chemotherapy to 3.77 gm/dl after chemotherapy, in agreement with authors found that low levels of serum albumin may be related to many factors as biological stress, liver dysfunction, and decrease mass of visceral protein or ability of albumin synthesizing. Also association with marked malnutrition [5,16,17&18] In 13] , this difference explained by the higher prevalence of HBV in community of these studies than our community.
Ten patients (11.3%) were HBsAg negative/antiHBc positive which is slightly lower than that (12%) reported by Pattullo[11] . while markedly lower than that reported by Kawsar et al., in Regarding HCV patients: Nine patients (10.2%) had positive result for HCV Ab, before treatment from whom 1 patient completed antiviral therapy with DAAS since 3 years and achieved SVR, 2 patients had negative HCV RNA by PCR, while the other 6 patients had positive HCV RNA by PCR with mean of 698352 IU/ ml which increased to 2609409 IU/ ml after chemotherapy. While Miura et. al. in a retrospective survey of patients diagnosed with breast cancer in Japan reported that 20 patients (2%) were HCV Ab positive; this difference may be due to difference of HCV prevalence between Egypt & Japan [7]. Also Miura et. al. reported no difference in HCV RNA PCR before after chemotherapy with median serum HCV-RNA level at baseline and after chemotherapy was 6.4 and 6.5 log IU/ml, respectively. While Coppola et. al. showed that rituximab-based chemotherapy resulted in an increase in HCV-RNA at least 1.5 log IU/ml followed by hepatic flare among patients with lymphoma [8] . These numerical differences are possibly due to the type or intensity of chemotherapy used for these conditions, rather than the nature of the malignancy itself and to the type of HCV infection [15].
CONCLUSION
Chemotherapy for breast cancer carries high risk for hepatotoxicity. Hepatotoxicity and liver morbidity is more common in patients with viral hepatitis and liver disease before starting chemotherapy, with probability of reactivation of HBV and HCV infections after chemotherapy. Prophylactic antiviral therapy by Tenofovir 300 mg once daily decreases risk of HBV reactivation.
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